Phase I Evaluation of ABBV-525, a MALT1 Inhibitor, in Patients with B-Cell Malignancies

The primary objective of this study is to evaluate the safety and tolerability of **ABBV-525**, a MALT1 inhibitor, in patients with various **B-cell malignancies**. This is clinically relevant as it aims to determine the potential therapeutic benefits and risks associated with the novel treatment, which could lead to advancements in managing these types of cancers. No secondary objectives are provided in the available data.

The clinical trial involves a total of **62 participants** diagnosed with **various B-cell malignancies**. The study population includes both male and female subjects, with an age range that spans from young adults to older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided information regarding the main objective of the trial or the principal inclusion criteria. The selection process aimed to encompass a diverse group of individuals affected by the specified medical condition, ensuring a comprehensive evaluation of the investigational treatment across different demographics.

The clinical trial is designed to evaluate the safety and efficacy of **ABBV-525**, a MALT1 inhibitor, in patients with various **B-cell malignancies**. This is a Phase 1 trial, characterized by a randomized, double-blind, and controlled design, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thereby minimizing bias. The trial is expected to commence recruitment on October 16, 2023, and is projected to conclude by September 1, 2027, marking an overall duration of approximately four years.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess the drug's safety profile, and evaluate its therapeutic effects. The end-of-study visit marks the final assessment, where comprehensive data collection is performed to conclude the participant's involvement in the trial.

The expected length of participant involvement varies, depending on individual response and tolerance to the treatment. However, participants are generally expected to remain in the study until its completion unless specific conditions necessitate early termination. Such conditions may include adverse reactions, withdrawal of consent, or any other medical reasons deemed significant by the study investigators. The trial's structured approach ensures rigorous monitoring and data collection, contributing to the understanding of **ABBV-525**'s potential in treating **B-cell malignancies**.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is October 16, 2023, with an anticipated end date of September 1, 2027. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy through various measures, which may include symptom improvement scores, biomarker levels, or other relevant clinical indicators. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial's efficacy assessments are expected to be conducted using scientifically validated tools and instruments appropriate for the medical condition under investigation. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.